CDK4 and prostate carcinoma: In contrast, miR-486 inhibits cell proliferation and invasion through repressing GAB2, PIK3R1, Snail, neuropilin-2, CDK4, or PIM-1 in non-small-cell lung cancer, colorectal cancer, prostate cancer, hepatocellular carcinoma, and breast cancer cells [34,35,36,37,38,39,40].